Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HuCD33 BsAb - Y-mAbs Therapeutics

Drug Profile

HuCD33 BsAb - Y-mAbs Therapeutics

Alternative Names: huCD33-Bispecific antibody - Y-mAbs Therapeutics; huCD33-BsAb (CD33xCD3); huCD33-BsAb - Y-mAbs Therapeutics

Latest Information Update: 09 Jun 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Memorial Sloan-Kettering Cancer Center; Y-mAbs Therapeutics
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD3 antigen inhibitors; CD33 antigen inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia
  • No development reported Haematological malignancies

Most Recent Events

  • 25 May 2023 Y-mAbs Therapeutics terminates a phase I trial in Acute myeloid leukemia (In children, In adolescents, In adults, Second-line therapy or greater) in USA (SC), due to business priorities) (NCT05077423)
  • 28 Sep 2022 No recent reports of development identified for preclinical development in Haematological-malignancies in USA (Parenteral)
  • 18 May 2022 Phase-I clinical trials in Acute myeloid leukaemia (In adults, In children, In adolescents, Second-line therapy or greater) in USA (SC) (NCT05077423)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top